Investment
Features
FeesSafety
Academy
More
Pluang+

Compare The Coca-Cola Co K (KO) vs Revvity Inc (RVTY) Price & Performance

The Coca-Cola Co KTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

The Coca-Cola Co K vs Revvity Inc — how do they compare? The Coca-Cola Co K trades at $88.09 (market cap $377.63B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: The Coca-Cola Co K is far larger — about 22.2× Revvity Inc's market cap, and The Coca-Cola Co K pays the higher dividend (2.42%). Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Revvity Inc for 12 Days on average.

KORVTY
Market Cap
$377.63B$16.98B
Volume
14,894,5681,456,900
Sector
Consumer StaplesHealth
52-Week High
$91.99$157.36
52-Week Low
$66.37$82.26
Typical Hold Time
154 Days12 Days
Enterprise Value
$404.81B$19.30B
Dividend Yield
2.42%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

The Coca-Cola Co K

Coca-Cola (KO) trades at $88.05, up 2.6% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $0.97 versus $0.92, maintaining a 61.89% gross margin and 28.56% net income margin. Recent institutional buying activity and positive analyst sentiment (60.42% buy ratings) support the stock's upward trajectory.

KO presents a compelling investment case with consistent earnings outperformance and a 64-year dividend growth streak. However, elevated valuation ratios (P/E 26.36, P/S 7.55) and regional demand divergence pose risks. The consensus price target of $95.75 suggests 8.7% upside potential from current levels, supported by strong cash flow generation and brand dominance.

Revvity Inc

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KO
17% Buy83% Sell
Avg holding period · 154 Days
RVTY
0% Buy100% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →